Seres Therapeutics Inc (MCRB) - Net Assets
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has net assets worth $26.50 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($117.62 Million) and total liabilities ($91.12 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Seres Therapeutics Inc (MCRB) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.50 Million |
| % of Total Assets | 22.53% |
| Annual Growth Rate | 16.09% |
| 5-Year Change | -66.38% |
| 10-Year Change | -66.66% |
| Growth Volatility | 1344.21 |
Seres Therapeutics Inc - Net Assets Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See MCRB days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Seres Therapeutics Inc (2012–2025)
The table below shows the annual net assets of Seres Therapeutics Inc from 2012 to 2025. For live valuation and market cap data, see how much is Seres Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $44.22 Million | +220.79% |
| 2024-12-31 | $13.78 Million | +130.73% |
| 2023-12-31 | $-44.86 Million | -515.99% |
| 2022-12-31 | $10.78 Million | -91.80% |
| 2021-12-31 | $131.51 Million | -24.75% |
| 2020-12-31 | $174.75 Million | +461.62% |
| 2019-12-31 | $-48.32 Million | -0.58% |
| 2018-12-31 | $-48.05 Million | -179.15% |
| 2017-12-31 | $60.70 Million | -54.23% |
| 2016-12-31 | $132.63 Million | -35.43% |
| 2015-12-31 | $205.39 Million | +868.66% |
| 2014-12-31 | $-26.72 Million | -4334.71% |
| 2013-12-31 | $631.00K | -90.08% |
| 2012-12-31 | $6.36 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Seres Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 96804800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.02% |
| Other Components | $1.02 Billion | 2299.09% |
| Total Equity | $44.22 Million | 100.00% |
Seres Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Seres Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Newbridge Acquisition Limited Class A Ordinary Share
NASDAQ:NBRG
|
$60.84 Million |
|
tsh biopharmoration Ltd
TWO:8432
|
$60.85 Million |
|
Italian-Thai Development Public Company Limited
BK:ITD
|
$60.89 Million |
|
Westlin Corporation
NASDAQ:WSTN
|
$60.91 Million |
|
Farmsco
KO:036580
|
$60.75 Million |
|
Alliance Witan Ord
LSE:ALW
|
$60.74 Million |
|
Meta Biomed Co. Ltd
KQ:059210
|
$60.74 Million |
|
Halmont Properties Corporation
V:HMT
|
$60.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Seres Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,784,000 to 44,218,000, a change of 30,434,000 (220.8%).
- Net income of 5,696,000 contributed positively to equity growth.
- New share issuances of 13,167,000 increased equity.
- Other factors increased equity by 11,571,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $5.70 Million | +12.88% |
| Share Issuances | $13.17 Million | +29.78% |
| Other Changes | $11.57 Million | +26.17% |
| Total Change | $- | 220.79% |
Book Value vs Market Value Analysis
This analysis compares Seres Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.30x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.98x to 1.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $3.27 | $6.46 | x |
| 2013-12-31 | $0.32 | $6.46 | x |
| 2014-12-31 | $-13.72 | $6.46 | x |
| 2015-12-31 | $174.56 | $6.46 | x |
| 2016-12-31 | $66.57 | $6.46 | x |
| 2017-12-31 | $30.01 | $6.46 | x |
| 2018-12-31 | $-23.58 | $6.46 | x |
| 2019-12-31 | $-17.06 | $6.46 | x |
| 2020-12-31 | $43.80 | $6.46 | x |
| 2021-12-31 | $28.68 | $6.46 | x |
| 2022-12-31 | $2.00 | $6.46 | x |
| 2023-12-31 | $-7.01 | $6.46 | x |
| 2024-12-31 | $1.77 | $6.46 | x |
| 2025-12-31 | $4.99 | $6.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Seres Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.88%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 721.93%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 3.13x
- Recent ROE (12.88%) is above the historical average (-337.89%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -49.15% | 0.00% | 0.00x | 1.03x | $-3.76 Million |
| 2013 | -967.04% | 0.00% | 0.00x | 3.37x | $-6.17 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.04 Million |
| 2015 | -26.67% | 0.00% | 0.00x | 1.06x | $-75.32 Million |
| 2016 | -69.05% | -420.74% | 0.08x | 2.06x | $-104.84 Million |
| 2017 | -147.25% | -278.44% | 0.17x | 3.12x | $-95.45 Million |
| 2018 | 0.00% | -350.03% | 0.23x | 0.00x | $-94.14 Million |
| 2019 | 0.00% | -203.68% | 0.26x | 0.00x | $-65.45 Million |
| 2020 | -51.00% | -268.33% | 0.10x | 1.96x | $-106.60 Million |
| 2021 | -49.87% | -45.25% | 0.41x | 2.70x | $-78.73 Million |
| 2022 | -2319.92% | -3509.50% | 0.02x | 32.35x | $-251.24 Million |
| 2023 | 0.00% | -90.02% | 0.35x | 0.00x | $-109.24 Million |
| 2024 | -1063.34% | 0.00% | 0.00x | 10.14x | $-147.95 Million |
| 2025 | 12.88% | 721.93% | 0.01x | 3.13x | $1.27 Million |
Industry Comparison
This section compares Seres Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Seres Therapeutics Inc (MCRB) | $26.50 Million | -49.15% | 3.44x | $60.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more